Merck & Company, Inc. (NYSE:MRK) – Equities research analysts at Jefferies Group lifted their FY2017 earnings per share (EPS) estimates for Merck & in a report released on Monday, Zacks Investment Research reports. Jefferies Group analyst J. Holford now forecasts that the company will earn $3.90 per share for the year, up from their prior forecast of $3.88. Jefferies Group has a “Underperform” rating on the stock. Jefferies Group also issued estimates for Merck &’s FY2018 earnings at $4.18 EPS, FY2019 earnings at $4.08 EPS, FY2020 earnings at $4.18 EPS and FY2021 earnings at $4.45 EPS.
A number of other brokerages have also recently weighed in on MRK. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and set a $74.00 price target (up from $70.00) on shares of Merck & in a research report on Thursday, July 27th. BMO Capital Markets set a $70.00 price target on shares of Merck & and gave the company a “buy” rating in a research report on Wednesday, October 11th. BidaskClub cut shares of Merck & from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Piper Jaffray Companies set a $70.00 price objective on shares of Merck & and gave the company a “buy” rating in a report on Saturday, July 29th. Finally, Credit Suisse Group dropped their price objective on shares of Merck & from $75.00 to $74.00 and set an “outperform” rating for the company in a report on Wednesday, August 30th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $67.07.
WARNING: “Merck & Company, Inc. to Post FY2017 Earnings of $3.90 Per Share, Jefferies Group Forecasts (NYSE:MRK)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2017/11/12/merck-company-inc-to-post-fy2017-earnings-of-3-90-per-share-jefferies-group-forecasts-mrk.html.
Shares of Merck & (NYSE:MRK) traded down $0.73 on Wednesday, hitting $55.48. 16,743,801 shares of the company’s stock were exchanged, compared to its average volume of 9,494,131. Merck & has a 1-year low of $54.41 and a 1-year high of $66.80. The firm has a market capitalization of $153,140.61, a PE ratio of 14.45, a PEG ratio of 2.42 and a beta of 0.78. The company has a current ratio of 1.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.57.
Merck & (NYSE:MRK) last announced its quarterly earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.08. Merck & had a net margin of 11.60% and a return on equity of 27.08%. The business had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. During the same period last year, the business earned $1.07 earnings per share. The business’s revenue for the quarter was down 2.0% on a year-over-year basis.
In other news, Director Thomas H. Glocer sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.25% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the company. Fort Washington Investment Advisors Inc. OH lifted its position in shares of Merck & by 133.4% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 144,247 shares of the company’s stock worth $9,165,000 after buying an additional 82,454 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Merck & by 2.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,206,648 shares of the company’s stock worth $269,678,000 after buying an additional 107,201 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH lifted its position in shares of Merck & by 41.9% during the 2nd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 296,294 shares of the company’s stock worth $19,028,000 after buying an additional 87,443 shares during the last quarter. Stevens Capital Management LP purchased a new stake in shares of Merck & during the 1st quarter worth approximately $15,126,000. Finally, Trust Co lifted its position in shares of Merck & by 2.8% during the 1st quarter. Trust Co now owns 68,789 shares of the company’s stock worth $4,371,000 after buying an additional 1,852 shares during the last quarter. Institutional investors and hedge funds own 72.84% of the company’s stock.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Get a free copy of the Zacks research report on Merck & (MRK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.